drugset / Trial / NCT06678282
JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia
NaSingle-groupOpen-labelTreatment
Summary
This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed or refractory B cell lymphoma / leukemia. It is an early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of relapsed or refractory B cell lymphoma / leukemia.
Timeline
- Start
- 2023-09-07
- Primary completion
- 2026-09-30
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JY231 | Cell therapy | 1e+06 unknown | Intravenous |
| Subject | JY231 | Cell therapy | 2e+07 unknown | Intravenous |
| Subject | JY231 | Cell therapy | 6e+07 unknown | Intravenous |